10-Q: Immunovant Q2 Loss Widens Amid IMVT-1402 Clinical Push

Immunovant reports increased net loss in Q2 2025 as it accelerates development of its lead FcRn inhibitor, IMVT-1402, across multiple autoimmune indications.

Summary

• Net loss for the three months ended September 30, 2025, was $126.5 million, compared to $109.1 million for the prior-year period.
• Net loss for the six months ended September 30, 2025, was $247.1 million, compared to $196.3 million for the prior-year period.
• Cash and cash equivalents totaled $521.9 million as of September 30, 2025, a decrease from $714.0 million on March 31, 2025.
• Research and development (R&D) expenses increased by $17.0 million to $114.2 million for the three months, and by $42.7 million to $215.4 million for the six months, primarily due to IMVT-1402 trial initiations and higher headcount.
• General and administrative (G&A) expenses decreased by $1.0 million to $17.5 million for the three months, but increased by $6.3 million to $43.5 million for the six months, due to higher personnel-related expenses and a one-time stock-based compensation charge for the former CEO's retirement.
• Initiated potentially registrational trials for IMVT-1402 in Graves' disease (GD), difficult-to-treat rheumatoid arthritis (D2T RA), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), and Sjögren's disease (SjD).
• Initiated a proof-of-concept trial for IMVT-1402 in cutaneous lupus erythematosus (CLE).
• Top-line results for both batoclimab Phase 3 TED studies are now anticipated concurrently in the first half of calendar year 2026, a delay from the previously expected 'before the end of calendar year 2025' for the first study.
• Six-month off-treatment data from batoclimab Phase 2 GD trial showed approximately 80% (17/21) of subjects maintained T3/T4 values ≤ ULN at Week 48, with pathogenic TRAb levels remaining suppressed.

Sentiment

Score: 4

Explanation: While the company is aggressively advancing its lead candidate IMVT-1402 into multiple registrational trials, indicating strong pipeline progression, the significant increase in net losses and cash burn, coupled with a delay in batoclimab TED trial readouts and explicit statements about the need for future capital, points to increased financial pressure and execution risk. The positive batoclimab GD data is encouraging but overshadowed by the strategic shift to IMVT-1402 and the associated costs.

Positives

• Initiation of multiple potentially registrational trials for IMVT-1402 across five indications (GD, D2T RA, MG, CIDP, SjD) demonstrates rapid pipeline advancement.
• IMVT-1402 is being developed with a potentially best-in-class profile, aiming for approximately 80% IgG reductions with minimal off-target effects (albumin/LDL cholesterol).
• Positive six-month off-treatment data from batoclimab Phase 2 GD trial showed strong durability of response (80% maintained T3/T4 values at Week 48) and sustained TRAb suppression.
• General and administrative expenses decreased by $1.0 million for the three months ended September 30, 2025, reflecting effective cost management strategies.
• Leveraging data and insights from batoclimab trials to inform and accelerate IMVT-1402 development.

Negatives

• Net loss significantly widened to $126.5 million for the three months and $247.1 million for the six months ended September 30, 2025, compared to prior-year periods.
• Cash and cash equivalents decreased by $192.1 million from March 31, 2025, to September 30, 2025, indicating a high cash burn rate.
• R&D expenses increased substantially due to the acceleration of IMVT-1402 trials, contributing to increased losses.
• Delay in reporting top-line results for both batoclimab Phase 3 TED studies to the first half of calendar year 2026, from an initial expectation of the first study reading out by end of calendar year 2025.
• Accumulated deficit reached $1,486.6 million as of September 30, 2025.

Risks

• Uncertainties related to clinical effectiveness of products, commercialization, and regulatory approvals.
• Dependence on key products (IMVT-1402, batoclimab), key personnel, and third-party service providers (CROs).
• Need and ability to obtain additional financing; if not available, may be required to delay development.
• Risks related to the HanAll Agreement, including potential material breach, contract interpretation disputes, or termination, which could adversely affect development and commercialization rights.
• Potential disputes with HanAll regarding batoclimab development or commercialization plans, which could be expensive and time-consuming.
• Impact of macroeconomic and geopolitical factors (inflation, interest rates, international trade policies, Russia-Ukraine war, Middle East conflict) on operations, financial results, and clinical trial plans/timelines.
• Inherent limitations on the effectiveness of internal control systems, which can provide only reasonable, not absolute, assurance against error and fraud.

Future Outlook

Immunovant expects its existing cash and cash equivalents of $521.9 million as of September 30, 2025, to fund operating expenses and capital expenditure requirements for announced indications through the GD readout expected in 2027. The company anticipates continued significant expenses and net losses for the foreseeable future, with future capital requirements increasing as development programs advance, new trials are launched, manufacturing scales up, and commercialization infrastructure is built.

Management Comments

• Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.
• We believe that FcRn inhibition has broad therapeutic and commercial potential to address pathogenic IgG-mediated autoimmune diseases in several therapeutic areas, including but not limited to, endocrinology, neurology, rheumatology and dermatology.
• We expect to be able to reach approximately 80% IgG reductions with continued weekly dosing of 600 mg of IMVT-1402, offering deeper IgG reductions than observed with other competitor anti-FcRn programs.
• We are pursuing the rapid development of IMVT-1402 because of its best-in-class potential, with the 600 mg dose expected to reach approximately 80% IgG reduction.
• We believe IMVT-1402s profile has the potential to offer best-in-class efficacy, in addition to its potentially favorable safety profile and convenient administration with a simple self-administered auto-injector expected at launch.
• Our primary focus is to execute these six indications first, with plans to assess new indications for IMVT-1402 in the future.
• We do not currently, however, expect such legal proceedings to have a material adverse effect on our business, operating results or financial condition.

Industry Context

The filing highlights that FcRn inhibition has broad therapeutic and commercial potential, with third-party estimates suggesting over four million patients in the U.S. and Europe could benefit across more than 20 indications. Two approved FcRn inhibitors have already reached billions in global annual sales, indicating a robust and growing market for this class of drugs. Immunovant aims to position IMVT-1402 as a "best-in-class" FcRn inhibitor, suggesting a competitive landscape where differentiation in efficacy and safety profile is crucial.

Comparison to Industry Standards

• IMVT-1402 is expected to reach approximately 80% IgG reductions with weekly 600 mg dosing, which is stated to offer "deeper IgG reductions than observed with other competitor anti-FcRn programs."
• Consistent evidence across the class in eight indications in Phase 2 and 3 trials with FcRn inhibitors shows that deeper IgG reductions correlate with meaningful improvements in clinical outcomes.
• Immunovant's own Phase 2 and 3 studies with batoclimab in GD, MG, and CIDP validated that IgG reductions of greater than or equal to 70% led to meaningfully better outcomes compared to reductions below 70%.
• IMVT-1402 demonstrated "no or minimal reductions in albumin and no or minimal increases in LDL cholesterol levels," which are "off-target effects observed in some anti-FcRn antibodies, including batoclimab."
• All IMVT-1402 studies are using the YpsoMate autoinjector, which is "utilized for multiple approved products," suggesting a standard and accepted delivery device.

Management Changes

Corporate Governance

Legal Proceedings

• No material legal proceedings were party to as of September 30, 2025, and no contingent liabilities were recorded.
• The company may be subject to various lawsuits, claims, and other legal matters from time to time in the ordinary course of business.

Related Party Transactions

• Services Agreements with Roivant Sciences Ltd. (RSL) and Roivant Sciences GmbH (RSG) for development, administrative, and financial activities. RSI assigned its Services Agreement to RSL effective April 1, 2025.
• Expenses recorded under Services Agreements: $0.8 million for six months ended September 30, 2025 (vs. $0.4 million for prior year); de minimis for three months ended September 30, 2025 (vs. $0.3 million for prior year).
• Information Sharing and Cooperation Agreement with RSL, obligating the company to provide financial statements and other information, and comply with certain policies. No amounts paid or received under this agreement.
• RSL holds 10,000 shares of Series A preferred stock.
• Stock-based compensation expense related to RSL RSUs issued by RSL to company employees: $0.3 million for six months ended September 30, 2025 (vs. de minimis for prior year); $0.2 million for three months ended September 30, 2025 (vs. de minimis for prior year).

Stakeholder Impact

• Shareholders: Potential dilution from future equity raises, increased R&D expenses leading to wider losses, but also potential long-term value creation from advancing IMVT-1402. Delay in TED results could impact investor sentiment.
• Employees: Higher headcount in R&D, stock-based compensation, but also potential for increased workload with multiple clinical trials.
• Customers (future patients): Potential for new treatments for autoimmune diseases with IMVT-1402, which is positioned as a best-in-class FcRn inhibitor.
• Creditors: Increased financial risk due to significant losses and reliance on future capital raises.
• Suppliers/CROs: Continued and increased engagement for clinical trials and manufacturing activities.

Next Steps

• Continue to fund operations and conduct product research and development.
• Raise additional capital through equity, debt, or collaboration agreements.
• Execute IMVT-1402 trials in GD, D2T RA, MG, CIDP, SjD, and CLE.
• Manufacture IMVT-1402.
• Complete batoclimab trials.
• Prepare to seek regulatory approval for IMVT-1402 and potentially batoclimab.
• Assess new indications for IMVT-1402 in the future.
• Report initial results from IMVT-1402 D2T RA Period 1 open label portion in 2026.
• Report top-line results from IMVT-1402 CLE trial in 2026.
• Report top-line results from both batoclimab Phase 3 TED studies concurrently in the first half of calendar year 2026.
• Report top-line results from IMVT-1402 GD trials in 2027.
• Report top-line results from IMVT-1402 MG trial in 2027.
• Report top-line results from IMVT-1402 CIDP trial in 2028.
• Report top-line results from IMVT-1402 SjD trial in 2028.
• Make a final decision about the further development and regulatory submissions for batoclimab in the future.

Key Dates

Recommendation

Immunovant is making aggressive strides in advancing its IMVT-1402 pipeline into multiple registrational trials, which is a significant positive for long-term growth potential and addresses a large market. The promising profile of IMVT-1402 (deep IgG reduction, minimal off-target effects) and the positive batoclimab GD data are encouraging. However, the substantial increase in net losses and cash burn, coupled with the explicit need for future capital raises and the delay in batoclimab TED trial readouts, introduces considerable near-term financial and execution risk. The stock is likely to experience volatility as the market weighs the long-term potential against the immediate financial pressures and development delays. A "Hold" recommendation reflects the balance between the strong clinical progress and the heightened financial and operational risks.

Keywords

Immunovant, IMVT-1402, batoclimab, FcRn inhibitor, autoimmune diseases, Graves' disease, myasthenia gravis, CIDP, rheumatoid arthritis, Sjögren's disease, cutaneous lupus erythematosus, clinical trials, biopharmaceutical, SEC filing, 10-Q, drug development, R&D, cash burn, liquidity, HanAll Biopharma, regulatory approval